Cargando…
A Propensity Score Matched Comparison of Brand and Biosimilar Basal Insulin in Non-Critical Hospitalized Patients with Type 2 Diabetes Mellitus
INTRODUCTION: Comparisons between brand and biosimilar basal insulin in hospitalized patients are lacking. We aimed to compare the efficacy and safety of brand insulin glargine vs. biosimilar insulin glargine in non-critical hospitalized patients with type 2 diabetes mellitus (T2DM). METHODS: This r...
Autores principales: | Hu, Xia, Zhang, Lei, Dong, Chao, Dong, Yanhu, Jiang, Jikang, Gao, Weiguo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824369/ https://www.ncbi.nlm.nih.gov/pubmed/30900200 http://dx.doi.org/10.1007/s12325-019-00922-9 |
Ejemplares similares
-
Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review
por: Hu, Xia, et al.
Publicado: (2018) -
Financial Conflicts of Interest in Propensity Score-Matched Studies Evaluating Biologics and Biosimilars for Inflammatory Bowel Disease
por: Elsolh, Karam, et al.
Publicado: (2022) -
Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
por: Heller, Simon, et al.
Publicado: (2023) -
A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study
por: Ito, Hiroyuki, et al.
Publicado: (2018) -
Cost and Utilization Comparisons Among Propensity Score-Matched Insulin Lispro and Regular Insulin Users
por: Hall, Jennifer A., et al.
Publicado: (2003)